Real-world outcomes of avelumab plus axitinib as first-line therapy in patients with advanced renal cell carcinoma in Japan: A multicenter, retrospective, observational study (J-DART).
Kato T, Nakano Y, Hongo F, Katano H, Miyagawa T, Ueda K, Azuma H, Nozawa M, Hinata N, Hori J, Otoshi T, Shimizu N, Aizawa M, Osada S, Matsui A, Oya M, Eto M, Tomita Y, Shinohara N, Uemura H.
Kato T, et al. Among authors: osada s.
Int J Urol. 2024 Mar;31(3):265-272. doi: 10.1111/iju.15345. Epub 2023 Dec 18.
Int J Urol. 2024.
PMID: 38110838
Free PMC article.